HeartFlow (HTFL) has drawn investor attention after recent share price swings, with the stock up 3.7% on the day, but down 15.1% over the past month and 8.2% year to date.

That recent 1-day share price return sits against a 7-day share price return of down 9.6% and a 30-day share price return of down 15.1%, while the 90-day share price return of 12.3% hints at earlier momentum now fading.

If HeartFlow’s swings have you thinking more broadly about healthcare AI, it could be a good moment to scan the market for other ideas using our screener of 29 healthcare AI stocks.

With shares down over the past month but still above their 90 day level, and analysts setting a higher price target than today’s US$26.60, you have to ask: is HeartFlow undervalued or already pricing in future growth?

Most Popular Narrative: 31.1% Undervalued

Analysts following HeartFlow see fair value at $38.60 versus the last close at $26.60, and link that gap to how its AI driven cardiac platform scales.

The transition of HeartFlow Plaque Analysis to a Category 1 CPT code in 2026, with defined Medicare payment rates in both clinic and hospital settings and commercial coverage already at 57% of U.S. lives, sets up a path for more routine clinical use that can add a new revenue stream and support gross margin mix over time.

Want to understand why this valuation leans so heavily on future growth rather than current earnings? Revenue expansion, margin uplift and a punchy future profit multiple sit at the core of this story.

Result: Fair Value of $38.60 (UNDERVALUED)

However, this story depends on coronary CT use and Plaque Analysis adoption staying on track, while heavy spending on sales and R&D could keep losses elevated if case growth lags.

Another View: Expensive on Sales

Those analyst targets describe HeartFlow as 31.1% undervalued, but our DCF work tells a very different story. On Simply Wall St’s DCF model, the stock at $26.60 is trading well above an estimated value of $6.30, which points to a rich price rather than a bargain. Which story do you lean toward?

Next Steps

Conflicted by the mix of optimism and concern running through this story? Take a closer look at the facts and timing for yourself by starting with the 3 key rewards and 2 important warning signs.

Looking for more investment ideas?

If HeartFlow has sharpened your focus, now is the right time to widen your watchlist and uncover other opportunities that could suit your goals.

• Target income first by scanning for companies paying robust yields in the 12 dividend fortresses.
• Hunt for quality at a sensible price with the 54 high quality undervalued stocks.
• Prioritise capital preservation by checking the 66 resilient stocks with low risk scores before you miss out on sturdier options.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.